Day One To Sell Priority Review Voucher For $108M
Portfolio Pulse from Benzinga Newsdesk
Day One Biopharmaceuticals (DAWN) announced the sale of a Priority Review Voucher (PRV) for $108 million. As part of the transaction, $8.1 million will be paid to Viracta Therapeutics (VIRX) to satisfy PRV-related obligations under a license agreement.
May 30, 2024 | 12:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Day One Biopharmaceuticals (DAWN) has sold a Priority Review Voucher for $108 million, which will positively impact its cash reserves and financial position.
The sale of the PRV for $108 million will significantly enhance DAWN's cash reserves, improving its financial stability and potentially funding future projects.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Viracta Therapeutics (VIRX) will receive $8.1 million from Day One Biopharmaceuticals (DAWN) as part of the PRV sale, fulfilling PRV-related obligations.
The $8.1 million payment from DAWN will positively impact VIRX's financials by fulfilling PRV-related obligations, potentially improving its cash flow.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50